Abuse of reformulated OxyContin: Updated findings from a sentinel surveillance sample of individuals assessed for substance use disorder

Theresa A. Cassidy, MPH; Eileen Thorley, MPH; Ryan A. Black, PhD; Angela DeVeaugh-Geiss, PhD; Stephen F. Butler, PhD; Paul Coplan, ScD

doi:10.5055/jom.2017.0419

Authors

Theresa A. Cassidy, MPH
Eileen Thorley, MPH
Ryan A. Black, PhD
Angela DeVeaugh-Geiss, PhD
Stephen F. Butler, PhD
Paul Coplan, ScD

DOI:

https://doi.org/10.5055/jom.2017.0419

Keywords:

prescription opioid, abuse, ADFs, OxyContin, NAVIPPRO

Abstract

Objective: To examine abuse prevalence for OxyContin and comparator opioids over a 6-year period prior to and following market entry of reformulated OxyContin and assess consistency in abuse across treatment settings and geographic regions.

Design: An observational study examining longitudinal changes using cross-sectional data from treatment centers for substance use disorder.

Setting: A total of 874 facilities in 39 states in the United States within the National Addictions Vigilance Intervention and Prevention Program (NAVIPPRO^®) surveillance system.

Participants: Adults (72,060) assessed for drug problems using the Addiction Severity Index-Multimedia Version (ASI-MV®) from January 2009 through December 2015 who abused prescription opioids.

Main outcome measure(s): Percent change in past 30-day abuse.

Results: OxyContin had significantly lower abuse 5 years after reformulation compared to levels for original OxyContin. Consistency of magnitude in OxyContin abuse reductions across geographic regions, ranging from 41 to 52 percent with differences in abuse reductions in treatment setting categories occurred. Changes in geographic region and treatment settings across study years did not bias the estimate of lower OxyContin abuse through confounding.

Conclusion: In the postmarket setting, limitations and methodologic challenges in abuse measurement exist and it is difficult to isolate singular impacts of any one intervention given the complexity of prescription opioid abuse. Expectations for a reasonable threshold of abuse for any one ADF product or ADF opioids as a class are still uncertain and undefined. A significant decline in abuse prevalence of reformulated OxyContin was observed 5 years after its reformulation among this treatment sample of individuals assessed for substance use disorder that was lower historically for the original formulation of this product.

Author Biographies

Theresa A. Cassidy, MPH

Inflexxion, Inc., Waltham, Massachusetts

Eileen Thorley, MPH

PatientsLikeMe, Inc., Cambridge, Massachusetts

Ryan A. Black, PhD

Nova Southeastern University, Fort Lauderdale, Florida

Angela DeVeaugh-Geiss, PhD

Purdue Pharma, LP, Stanford, Connecticut

Stephen F. Butler, PhD

Inflexxion, Inc., Waltham, Massachusetts

Paul Coplan, ScD

Purdue Pharma, L.P, Stanford, Connecticut; Adjunct, University of Pennsylvania Perelman School of Medicine, Philadelphia, Pennsylvania

References

Substance Abuse and Mental Health Services Administration (SAMSHA): Behavioral Health Trends in the United States: Results from the 2014 National Survey on Drug Use and Health; 2015. Available at https://www.samhsa.gov/data/sites/default/files/NSDUH-FRR1-2014/NSDUH-FRR1-2014.pdf. Accessed February 18, 2016.

Okie S: A flood of opioids, a rising tide of deaths. N Engl J Med. 2010; 363 (21): 1981-1985.

Dart RC, Surratt HL, Cicero TJ, et al.: Trends in opioid analgesic abuse and mortality in the United States. N Engl J Med. 2015; 372 (3): 241-248.

Substance Abuse and Mental Health Services Administration, Center for Behavioral Health Statistics and Quality. Treatment Episode Data Set (TEDS) 2002-2012, National Admissions to Substance Abuse Treatment Services. BHSIS Series s-71. HHS Publication No. 14-4850. Substance Abuse and Mental Health Services Administration, Rockville, MD. 2014.

Compton WM, Jones CM, Baldwin GT: Relationship between nonmedical prescription-opioid use and heroin use. N Engl J Med. 2016; 374: 154-163.

Office of National Drug Control Policy (ONDCP): National Drug Control Strategy. 2015. Available at https://www.whitehouse.gov//sites/default/files/ondcp/policy-and-research. Accessed August 24, 2016.

Delcher C, Wagenaar A, Goldberger BA, et al.: Abrupt decline in oxycodone-caused mortality after implementation of Florida's Prescription Drug Monitoring Program. Drug Alcohol Depend. 2015; 150: 63-68.

Rasubala L, Pernapati L, Velasquez X, et al.: Impact of a mandatory prescription drug monitoring program on prescription of opioid analgesics by dentists. PLoS One. 2015; 10 (8): e0135957.

Kirsh K, Peppin J, Coleman J: Characterization of prescription opioid abuse in the United States: focus on route of administration. J Pain Palliat Care Pharmacother. 2012; 26 (4): 348-361.

Butler SF, Black RA, Cassidy TA: Abuse risks and routes of administration of different prescription opioid compounds and formulations. Harm Reduct J. 2011; 8 (1): 29. doi:10.1186/1477-7517-8-29.

Katz N, Dart RC, Bailey E, et al.: Tampering with prescription opioids: nature and extent of the problem, health consequences, and solutions. Am J Drug Alcohol Abuse. 2011; 37 (4): 205-217. doi:10.3109/00952990.2011.569623.

Gasior M, Bond M, Malamut R: Routes of abuse of prescription opioid analgesics: A review and assessment of the potential impact of abuse-deterrent formulations. Postgrad Med. 2016; 128 (1): 85-96. doi:10.1080/00325481.2016.1120642.

Hale ME, Moe D, Bond M, et al.: Abuse-deterrent formulations of prescription opioid analgesics in the management of chronic noncancer pain. Pain Manag. 2016; 6 (5): 497-508. doi:10.2217/pmt-2015-0005.

FDA, CDER: Abuse-Deterrent Opioids—Evaluation and Labeling Guidance for Industry. 2015. Available at http://www.fda.gov/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/default.htm. Accessed July 18, 2016.

Keyes KM, Cerdá M, Brady JE, et al.: Understanding the rural–urban differences in nonmedical prescription opioid use and abuse in the United States. Am J Public Health. 2014; 104 (2): e52-e59.

Substance Abuse and Mental Health Services Administration (SAMSHA): 2013-2014 National Survey on Drug Use and Health National Maps of Prevalence Estimates by State. Available at http://www.samsha.gov/data. Accessed May 12, 2016.

National Institute on Drug Abuse Community Epidemiology Working Group: Epidemiologic Trends In Drug Abuse; 2014.

Green TC, Black R, Grimes Serrano JM, et al.: Typologies of prescription opioid use in a large sample of adults assessed for substance abuse treatment. PLoS One. 2011; 6 (11): e27244.

National Institute on Drug Abuse: Principles of Drug Addiction Treatment, A Research-Based Guide. 3rd edition. NIH Publication No. 12-4180. U.S. Department of Health and Human Services, National Institutes of Health, Bethesda, MD. December 2012.

Greenfield SF, Back SE, Lawson K, et al.: Substance abuse in women. Psychiatr Clin North Am. 2010; 33 (2): 339-355.

Grella CE: From generic to gender-responsive treatment: Changes in social policies, treatment services, and outcomes of women in substance abuse treatment. J Psychoactive Drugs. 2008; Suppl 5: 327-343.

Tiet QQ, Ilgen MA, Byrnes HF, et al.: Treatment setting and baseline substance use severity interact to predict patients’ outcomes. Addiction. 2007; 102 (3): 432-440.

Butler SF, Cassidy TA, Chilcoat H, et al.: Abuse rates and routes of administration of reformulated extended-release oxycodone: Initial findings from a sentinel surveillance sample of individuals assessed for substance abuse treatment. J Pain. 2012; 9. doi:10.1016/j.jpain.2012.08.008.

Coplan PM, Kale H, Sandstrom L, et al.: Changes in oxycodone and heroin exposures in the National Poison Data System after introduction of extended-release oxycodone with abuse-deterrent characteristics. Pharmacoepidemiol Drug Saf. 2013; 22 (12): 1274-1282.

Havens JR, Leukefeld CG, DeVeaugh-Geiss AM, et al.: The impact of a reformulation of extended-release oxycodone designed to deter abuse in a sample of prescription opioid abusers. Drug Alcohol Depend. 2014; 139: 9-17.

Hays L: A profile of OxyContin addiction. J Addict Disord. 2008; 23 (4): 1-9.

Severtson SG, Bartelson BB, Davis JM, et al.: Reduced abuse, therapeutic errors, and diversion following reformulation of extended-release oxycodone in 2010. J Pain. 2013; 14 (10): 1122-1130.

Coplan P, Chilcoat H, Butler S, et al.: The effect of an abuse-deterrent opioid formulation (OxyContin) on opioid abuse-related outcomes in the postmarketing setting. Clin Pharmacol Ther. 2016; 100 (3): 275-286.

Cicero TJ, Ellis MS, Harney J: Shifting patterns of prescription opioid and heroin abuse in the United States. N Engl J Med. 2015; 373 (18): 1789-1790.

Severtson SG, Ellis MS, Kurtz SP, et al.: Sustained reduction of diversion and abuse after introduction of an abuse deterrent formulation of extended release oxycodone. Drug Alcohol Depend. 2016; 168: 219-229.

Sessler NE, Downing JM, Kale H, et al.: Reductions in reported deaths following the introduction of extended-release oxycodone (OxyContin) with an abuse-deterrent formulation. Pharmacoepidemiol Drug Saf. 2014; 23 (12): 1238-1246.

Cone E, Giordano J, Weingarten B: An iterative model for in vitro laboratory assessment of tamper resistant formulations. Drug Alcohol Depend. 2013; 1-2: 100-105.

Harris SC, Perrino PJ, Smith I, et al.: Abuse potential, pharmacokinetics, pharmacodynamics, and safety of intranasally administered crushed oxycodone HCl abuse-deterrent controlled-release tablets in recreational opioid users. J Clin Pharmacol. 2014; 54 (4): 468-477.

FDA: FDA News Release. FDA approves abuse-deterrent labeling for reformulated OxyContin (April 16, 2013). Available at http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/ucm348252.htm. Accessed August 24, 2016.

Butler SF, Budman SH, Licari A, et al.: National Addictions Vigilance Intervention and Prevention Program (NAVIPPRO): A real-time public health surveillance system for monitoring prescription drug abuse. Pharmacoepidemiol Drug Saf. 2008; 17(12): 1142-1154.

Butler SF, Newman FL, Cacciola JS, et al.: Predicting addiction severity index (ASI) interviewer severity ratings for a computer- administered ASI. Psychol Assessment. 1998; 10 (4): 399-407.

Butler SF, Budman SH, Goldman RJ, et al.: Initial validation of a computer-administered Addiction Severity Index: The ASI-MV. Psychol Addict Behav. 2001; 15 (1): 4-12.

McLellan AT, Luborsky L, Woody GE, et al.: An improved diagnostic evaluation instrument for substance abuse patients. The Addiction Severity Index. J Nerv Ment Dis. 1980; 168 (1): 26-33.

McLellan AT, Luborsky L, Cacciola J, et al.: New data from the Addiction Severity Index. Reliability and validity in three centers. J Nerv Ment Dis. 1985; 173 (7): 412-423.

McLellan A, Kushner H, Metzger D, et al.: The fifth edition of the addiction severity index. J Subst Abuse Treat. 1992; 9 (3): 199-213.

Kosten T, Rounsaville B, Kleber H.: Concurrent validity of the addiction severity index. J Nerv Ment Disord. 1983; 171 (10): 606-610.

QuintilesIMS.: Sub-National Prescription Drug Market Tracking, Custom Pain Market Analysis [dataset]. distributed by QuintilesIMS Inc., Plymouth Meeting, PA 2016.

Cassidy TA, Dasmapatra P, Black RA, et al.: Changes in prevalence of prescription opioid abuse after introduction of an abuse-deterrent opioid formulation. Pain Med. 2014; 15(3): 440-451.